lonafarnib has been researched along with ro5126766 in 1 studies
| Studies (lonafarnib) | Trials (lonafarnib) | Recent Studies (post-2010) (lonafarnib) | Studies (ro5126766) | Trials (ro5126766) | Recent Studies (post-2010) (ro5126766) |
|---|---|---|---|---|---|
| 224 | 34 | 90 | 23 | 2 | 23 |
| Protein | Taxonomy | lonafarnib (IC50) | ro5126766 (IC50) |
|---|---|---|---|
| RAF proto-oncogene serine/threonine-protein kinase | Homo sapiens (human) | 0.056 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.16 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 0.16 | |
| Serine/threonine-protein kinase B-raf | Homo sapiens (human) | 0.0136 | |
| Dual specificity mitogen-activated protein kinase kinase 1 | Homo sapiens (human) | 0.16 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Laufer, S; Pillaiyar, T | 1 |
1 review(s) available for lonafarnib and ro5126766
| Article | Year |
|---|---|
Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; Protein Kinase Inhibitors; SARS-CoV-2; Signal Transduction; Virus Replication | 2022 |